GT Biopharma
GTBP
49 hedge funds and large institutions have $69.7M invested in GT Biopharma in 2021 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 4 closing their positions.
1,653% more capital invested
Capital invested by funds: $3.98M → $69.7M (+$65.7M)
725% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 4
145% more funds holding
Funds holding: 20 → 49 (+29)
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
0.62% more ownership
Funds ownership: 0.09% → 0.71% (+0.62%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$19.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$7.06M |
| 4 |
State Street
Boston,
Massachusetts
|
+$5.19M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$290K |
| 2 |
Millennium Management
New York
|
-$191K |
| 3 |
VF
Virtu Financial
New York
|
-$156K |
| 4 |
Squarepoint
New York
|
-$113K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$15K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Squarepoint
New York
| – | -$113K | -551 | Closed |
|
|
SPIA
52
Steward Partners Investment Advisory
New York
| – | -$198 | -1 | Closed |
|
53
Fidelity Investments
Boston,
Massachusetts
| – | +$416 | +1 | New |
|
GTBP Hedge Fund Activity: Q2 2021 in Review
49 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q2 2021, worth a combined $69.7M — up 1,653% from $3.98M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new GTBP positions and 4 closed out — a net gain of 29 holders — while 9 added to existing stakes and 4 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $19.6M. The largest seller was Royal Bank of Canada, cutting an estimated $290K.
- 49 institutional investors held GT Biopharma (GTBP) as of Q2 2021, up from 20 in Q1 2021.
- Funds reported $69.7M of GT Biopharma stock for Q2 2021, up 1,653% quarter-over-quarter.
- 33 funds opened new GT Biopharma positions in Q2 2021 and 4 closed out, a net change of +29 holders.
- The largest GT Biopharma buyer in Q2 2021 was BlackRock, an estimated $19.6M added.
- The largest GT Biopharma seller in Q2 2021 was Royal Bank of Canada, an estimated $290K sold.
Based on aggregated 13F filings for Q2 2021.